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Abstract
Background: Papillary thyroid carcinoma (PTCs), the most frequent thyroid cancer, is usually not life threatening, but may
recur or progress to aggressive forms resistant to conventional therapies. A more detailed understanding of the signaling
pathways activated in PTCs may help to identify novel therapeutic approaches against these tumors. The aim of this study is
to identify signaling pathways activated in PTCs.
Methodology/Principal Findings: We examined coordinated gene expression patterns of ligand/receptor (L/R) pairs using
the L/R database DRLP-rev1 and five publicly available thyroid cancer datasets of gene expression on a total of 41 paired
PTC/normal thyroid tissues. We identified 26 (up) and 13 (down) L/R pairs coordinately and differentially expressed. The
relevance of these L/R pairs was confirmed by performing the same analysis on REarranged during Transfection (RET)/PTC1-
infected thyrocytes with respect to normal thyrocytes. TGFA/EGFR emerged as one of the most tightly regulated L/R pair.
Furthermore, PTC clinical samples analyzed by real-time RT-PCR expressed EGFR transcript levels similar to those of 5 normal
thyroid tissues from patients with pathologies other than thyroid cancer, whereas significantly elevated levels of TGFA
transcripts were only present in PTCs. Biochemical analysis of PTC cell lines demonstrated the presence of EGFR on the cell
membrane and TGFA in conditioned media. Moreover, conditioned medium of the PTC cell line NIM-1 activated EGFR
expressed on HeLa cells, culminating in both ERK and AKT phosphorylation. In NIM-1 cells harboring BRAF mutation, TGFA
stimulated proliferation, contributing to PI3K/AKT activation independent of MEK/ERK signaling.
Conclusions/Significance: We compiled a reliable list of L/R pairs associated with PTC and validated the biological role of
one of the emerged L/R pair, the TGFA/EGFR, in this cancer, in vitro. These data provide a better understanding of the
factors involved in the biology of PTCs and would be useful in developing combination therapeutic approaches against
these cancers.
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Introduction
Thyroid cancer is the most prevalent malignancy of the endocrine
system. Its incidence has increased significantly over the last several
decades and it has become one of the 10 leading cancer types in
females [1]. Several tumor types originate from the thyroid epithelial
follicular cells and display different biological and clinical behaviors.
About 80% of thyroid tumors are papillary thyroid carcinoma (PTC).
Majority of the PTCs are not life threatening and are effectively
treated with thyroidectomy followed by radioactive iodine ablation
[2]. However, few PTCs recur or undergo progression from well-
differentiated carcinoma to either poorly or undifferentiated
carcinoma, and this last type is invariably fatal [3].
Many genetic alterations responsible for PTC initiation have
been identified. They are mutually exclusive and include BRAF
activating point mutations (up to 50% of cases), rearrangements of
the RET (30%) and NTRK1 (10%) receptor tyrosine kinase genes,
and RAS activating mutations (present almost exclusively in the
follicular variant of PTC) [4,5]. Thus, the constitutive activation of
one of the components of the RET(TRK)-RAS-BRAF-MAPK
signaling pathway appears necessary for the development of PTC.
Owing to hundreds of alterations that might be merely
consequential to transformation, the use of in vitro model of
human cells expressing known oncogenes was proposed as a useful
approach to focus on the pathogenic changes displayed by tumors.
In this context, we have successfully applied this approach using
primary human thyrocytes expressing the thyroid-specific RET/
PTC1 oncogene to model PTC, and we have demonstrated that
RET/PTC1 regulates the expression of a distinct set of genes
involved in inflammation and tumor invasion [6].
In the past few years, the possibility to obtain global molecular
profiles of tumors has provided answers to fundamental questions
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prognosis, and follow-up of tumors. Several groups, including ours,
have determined the gene expression profile of thyroid tumors.
Collectively, these studies have identified genes discriminating
between benign and malignant lesions, and among the latter,
specifically associated with follicular or papillary histotype [7].
With respect to PTC, specific gene expression signatures for
tumors carrying RTK rearrangements or BRAF mutations have
been detected [8,9]. To organize and analyze such a large volume
of information, new bioinformatic tools have been developed. One
of these, an algorithm based on the hypothesis that two gene
products participating in a common functional endpoint will have
correlated transcription levels, was designed for detecting
dysregulation of autocrine/paracrine ligand/receptor (L/R) sig-
naling loops [10]. On the basis of this algorithm, we implemented
the previously used L/R database [10], naming it DRLP-rev1
[11], and by a systematic meta-analysis of publicly available
epithelial ovarian cancer expression array datasets we gave in this
pathology the proof-of-principle of the statistical and biological
validity of the correlation of the L/R gene expression patterns
[11].
Here, we examined the gene expression patterns of L/R with
respect to their possible role as signaling pathways activated in
PTC. Using the DRLP-rev1 database to carry out meta-analysis of
five publicly available datasets that reported gene expression data
in thyroid cancer and normal thyroid tissues from the same
patients, we identified 26 (up) and 13 (down) L/R pairs that were
regulated in PTCs relative to their normal tissue counterparts. We
then compared these L/R pairs with those differentially expressed
in RET/PTC1-infected thyrocytes with respect to normal
thyrocytes. Both the analyses identified the coordinated expression
of the TGFA/EGFR L/R pair in tumor samples when compared
with normal tissue. To validate this in silico analysis, functional
experiments in thyroid cancer cell lines demonstrated the presence
of a functional TGFA/EGFR autocrine signaling loop, which
sustained the proliferation of PTC cells and contributed to the
activation of the PI3K/AKT pathway independent of MEK/ERK
pathway.
Results
Analysis of L/R pairs differentially expressed between
normal and tumor thyroid samples from PTC patients
To identify autocrine/paracrine loops of signaling activated in
transformed vs. normal thyroid cells, we analyzed 5 datasets
(Table 1), representing 41 patients, in which the gene expression
profiles of thyroid carcinoma samples were compared with those
from contralateral normal thyroid. First, the DLRP-rev1 gene list
was used to extract all the L/R pairs significantly correlated in
normal controlateral or in PTC samples Subsequently, a paired
t-test was used to identify significantly regulated Ligands and
Receptors in PTCs, relative to their normal counterparts (see
Materials and Methods for criteria of selection). By this analysis
26 and 13 L/R pairs were found up- and down-regulated,
respectively, in PTCs relative to their normal counterparts
(Table 2). Among the L/R pairs upregulated in tumor samples
were genes involved in: chemokine pathways (CCL13/CCR1, 2
datasets), growth pathways (INHBB/ACVR1, 4 datasets; TGFA/
EGFR, 2 datasets; TNC/ANXA2, 4 datasets), and motility and
adhesion (PLAU/PLAUR, 2 datasets; SEMA3F/NRP2, 4 data
sets; SPP1/ITGAV, 3 datasets; SPP1/CD44, 3 datasets; SPP1/
ITGA9, 2 datasets).
Among the downregulated L/R pairs were genes involved in
angiogenesis (ANGPTL1/TEK, 2 datasets; VEGF/FLT1, 2
datasets) and growth pathways (BMP2/BMPR1A, 2 data sets;
FGF13/FGFR2, 2 datasets).
Interestingly, the ligands PLAU and SPP1 have previously been
associated with invasion and progression in several types of solid
tumors, and both in vivo and in vitro models have demonstrated
overexpression of these ligands in thyroid tumors [12,13].
To test how the expression of the three L/R pairs involved in
growth pathways, INHBB/ACVR1, TNC/ANXA2, and TGFA/
EGFR, was regulated among 16 normal thyroid or 23 PTC
samples, a correlation analysis was performed between the pairs in
dataset III, which included the largest number of samples (see
Table 1). A significant inverse correlation was observed in the
thyroid cancer samples for the L/R pair INHBB/ACVR1
(P,0.05) (Fig. 1), but not in the normal samples. The expression
of the TNC/ANXA2 pair was directly correlated (P,0.05) only in
normal thyroid samples. For TGFA/EGFR, a significant direct
and inverse correlation was observed in normal and tumor
samples, respectively.
All together, these data show that the expression of INHBB,
ANXA2, and TGFA ligands could be specifically up-modulated in
PTCs vs. normal contralateral cells, thus supporting the hypothesis
that their differential expression is finely regulated in normal
tissues vs. tumor tissues. The signaling loops associated with the
pairs INHBB/ACVR1, TNC/ANXA2, and TGFA/EGFR ap-
peared to be relevant in the pathogenesis of PTCs.
EGFR-associated signaling loops are concordantly
up-modulated in RET/PTC1-infected thyrocytes and
tumor samples
Based on previous evidence from our laboratory that autocrine
signaling loops are detectable in RET/PTC1-infected thyrocytes
[6], we decided to test the relevance of the autocrine loops by
comparing the L/R pairs differentially expressed in PTCs vs.
normal contralateral tissues (see Table 2) with those differentially
expressed in RET/PTC1-infected thyrocytes vs. normal thyro-
Table 1. Characteristics of the explored datasets.
Code Ref. Year Platform Probesets/Clones PTC Normal contralateral
I Vasko V [37] 2007 U133Plus 2.0 47000 7 4
II GSE3678* 2006 U133 Plus 2.0 47000 7 7
III Jarzab B [38] 2005 Oligo (U133A) 22283 23 16
IV Aldred MA [39] 2004 Oligo (U95Av2) 12626 6 6
V Huang Y [40] 2001 Oligo (U95Av2) 12626 8 8
*For this dataset, a Geo accession number is given.
doi:10.1371/journal.pone.0012701.t001
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1.
Dataset (no. of
samples) I (4) II (7) III (16) IV (6) V (8)
L/R Gene Symbol T/N P-value T/N P-value T/N P-value T/N P-value T/N P-value
(FDR) (FDR) (FDR) (FDR) (FDR)
Angiogenesis
L ANGPTL1 0.20 0.0002 0.21 0.0010
(0.0177) (0.0221)
RT E K 0.70 0.0338 0.63 0.0064 0.63 0.0000
(0.2251) (0.0605) (0.0000)
L VEGF 0.60 0.0045 0.77 0.0005 0.56 0.0033
(0.0799) (0.0176) (0.0088)
R FLT1 0.53 0.0009 0.77 0.0218
(0.0206) (0.0410
R KDR 0.59 0.0132 0.71 0.0208
(0.0984) (0.0396)
R NRP1 0.77 0.0064
(0.0605)
Cytokines
L IFNA4 1.25 0.0467
(0.2013)
R IFNAR2 1.43 0.0161 1.43 0.0006 1.25 0.0097
(0.1074) (0.0020) (0.0362)
L IFNA7 1.25 0.0044
(0.0507)
R IFNAR2 1.43 0.0161 1.43 0.0006 1.25 0.0097
(0.1074) (0.0020) (0.0362)
L TNFSF10 0.40 0.0007 0.50 0.0004 0.77 0.0453
(0.0265) (0.0014) (0.1096)
R TNFRSF11B 0.10 0.0000 0.19 0.0001 0.18 0.0000
(0.0073) (0.0079) (0.0000)
Chemokines
L CCL13 1.79 0.0292 3.33 0.0004 5.00 0.0000
(0.2031) (0.0138) (0.0000)
R CCR3 1.11 0.0465
(0.2013)
R CCR1 2.00 0.0147 2.00 0.0002
(0.1016) (0.0007)
L CXCL12 0.20 0.0003 0.45 0.0054 0.29 0.0000 0.42 0.0005
(0.0216) (0.0529) (0.0003) (0.0047)
R CXCR4 0.40 0.0124
(0.1291)
Growth factors
L AREG 2.00 0.0163
(0.0322)
RE G F R 1.67 0.0122 1.67 0.0055 1.25 0.0217
(0.0937) (0.0134) (0.0609)
L BMP7 1.25 0.0030
(0.0424)
R ACVR1 1.67 0.0275 1.43 0.0001 2.00 0.0002 1.67 0.0003
(0.1474) (0.0004) (0.0036) (0.358)
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samples) I (4) II (7) III (16) IV (6) V (8)
L/R Gene Symbol T/N P-value T/N P-value T/N P-value T/N P-value T/N P-value
(FDR) (FDR) (FDR) (FDR) (FDR)
L BTC 1.25 0.0310
(0.1577)
RE G F R 1.67 0.0122 1.67 0.0055 1.25 0.0217
(0.0937) (0.0134) (0.0609)
R ERBB3 3.70 0.0011 3.33 0.0000 2.00 0.0003 1.43 0.0210 2.00 0.0039
(0.0373) (0.0006) (0.0012) (0.0609) (0.0871)
L DTR 2.50 0.0008
(0.0027)
RE G F R 1.67 0.0122 1.67 0.0055 1.25 0.0217
(0.0937) (0.0134) (0.0609)
L INHBA 5.00 0.0000
(0.0000)
R ACVR1 1.67 0.0275 1.43 0.0001 2.00 0.0002 1.67 0.0003
(0.1474) (0.0004) (0.0036) (0.0358)
L INHBB 2.38 0.0080 2.00 0.0112 2.00 0.0000 3.33 0.0000 2.50 0.0000
(0.1021) (0.0900) (0.0001) (0.0000) (0.0194)
R ACVR1 1.67 0.0275 1.43 0.0001 2.00 0.0002 1.67 0.0003
(0.1474) (0.0004) (0.0036) (0.0358)
L JAG2 1.79 0.0070 1.25 0.0050 1.43 0.0010
(0.0961) (0.0529) (0.0033)
R NOTCH2 1.25 0.0416
(0.1895)
R NOTCH3 1.69 0.0140
(0.1402)
L TGFA 4.17 0.0001 3.33 0.0000 5.00 ,1e-07
(0.0073) (0.0006) (,1e-07)
RE G F R 1.67 0.0122 1.67 0.0055 1.25 0.0217
(0.0937) (0.0134) (0.0609)
L TGFB1 2.38 0.0197 1.25 0.0192 2.00 0.0000 1.11 0.0195
(0.1652) (0.1190) (0.0001) (0.2025)
R TGFBR1 1.43 0.0050
(0.0529)
L TNC 2.50 0.0262 3.33 0.0004 2.00 0.0101 2.50 0.0188
(0.1453) (0.0014) (0.0362) (0.1996)
R ANXA2 1.43 0.0151 1.67 0.0000 1.67 0.0007 1.43 0.0076
(0.1024) (0.000) (0.0050) (0.1227)
L BMP2 0.20 0.0089 0.23 0.0002 0.45 0.0003
(0.1105) (0.0118) (0.0010)
R BMPR1A 0.50 0.0035 0.71 0.0033 0.53 0.0000
(0.0725) (0.0448) (0.0000)
L BMP7 0.40 0.0106 0.71 0.0371 0.59 0.0022
(0.1244) (0.1819) (0.0063)
R BMPR1A 0.50 0.0035 0.71 0.0033 0.53 0.0000
(0.0725) (0.0448) (0.0000)
L FGF7 0.63 0.0002
(0.0008)
Table 2. Cont.
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L/R Gene Symbol T/N P-value T/N P-value T/N P-value T/N P-value T/N P-value
(FDR) (FDR) (FDR) (FDR) (FDR)
R FGFR2 0.40 0.0041 0.43 0.0008 0.26 0.0000 0.83 0.0032
(0.796) (0.0206) (0.0000) (0.0149)
L FGF11 0.71 0.0095
(0.0803)
R FGFR2 0.40 0.0041 0.43 0.0008 0.26 0.0000 0.83 0.0032
(0.796) (0.0206) (0.0000) (0.0149)
L FGF13 0.53 0.0390 0.48 0.0005
(0.1841) (0.0018)
R FGFR2 0.40 0.0041 0.43 0.0008 0.26 0.0000 0.83 0.0032
(0.796) (0.0206) (0.0000) (0.0149)
L PTN 0.40 0.0015 0.53 0.0033 0.45 0.0006
(0.0503) (0.0448) (0.0020)
R PTPRB 0.63 0.0001
(0.0079)
L TGFB1 2.38 0.0197 1.25 0.0192 2.00 0.0000 1.11 0.0195
(0.1652) (0.1190) (0.0001) (0.2025)
R TGFBR2 0.50 0.0241 0.63 0.0005 0.67 0.0003
(0.1842) (0.0176) (0.0010)
R TGFBR3 0.40 0.0039 0.45 0.0004 0.45 0.0002
(0.0778) (0.0138) (0.0008)
Motility/adhesion
L EFNA3 1.49 0.0249
(0.1881)
R EPHA4 2.22 0.0032 2.00 0.0001 3.33 0.0002 1.43 0.0217
(0.0680) (0.0079) (0.0008) (0.2159)
L EFNA4 1.67 0.0166
(0.1094)
R EPHA4 2.22 0.0032 2.00 0.0001 3.33 0.0002 1.43 0.0217
(0.0680) (0.0079) (0.0008) (0.2159)
L LGALS1 2.00 0.0140 2.50 0.0000 2.00 0.0002 2.00 0.0026
(0.0984) (0.0001) (0.0036) (0.0769)
RS P N 1.25 0.0147
(0.1016)
L PLAU 4.35 0.0005 2.50 0.0232 2.40 0.0001 2.50 0.0003 3.33 0.0006
(0.0236) (0.1322) (0.0001) (0.0043) (0.0486)
R PLAUR 1.25 0.0069 3.33 0.0000
(0.0638) (0.0001)
L SEMA3F 2.33 0.0216 1.25 0.0183 1.67 0.0055 1.25 0.0496
(0.1783) (0.1159) (0.0134) (0.3115)
R NRP2 4.76 0.0028 2.50 0.0038 2.50 0.0000 1.11 0.0390
(0.0651) (0.0478) (0.0001) (0.2704)
L SEMA3B 1.11 0.0307
(0.1575)
R NRP2 4.76 0.0028 2.50 0.0038 2.50 0.0000 1.11 0.0390
(0.0651) (0.0478) (0.0001) (0.2704)
L SPP1 2.50 0.0015 3.33 0.0001 2.00 0.0003 2.00 0.0024
Table 2. Cont.
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expression between the two analyses (Table 3). Among these, four
EGFR ligand/EGFR pairs emerged, and in particular, TGFA was
robustly upregulated in the in vitro model (14.22-fold) as well as in
the PTC tumor samples (range: 3.3–5 fold). Elevated AREG
expression (148,50-fold increase) was observed in RET/PTC1-
infected thyrocytes with respect to normal thyrocytes. PLAU/
PLAUR, SPP1/CD44, and SPP1/ITGA9 were concordantly up-
regulated in the RET/PTC1-infected vs. normal thyrocytes
accordingly to that observed for PTC samples compared with
their normal counterparts.
Within the discordant L/R pairs, CXCL12/CXCR4 pair
emerged upregulated in RET/PTC1-infected thyrocytes with
respect to normal thyrocytes [6] and down-modulated in PTC
samples vs. the normal counterpart.
In summary, bioinformatic analysis identified frequent upregu-
lation of the L/R pair TGFA/EGFR in both RET/PTC1-
infected thyrocytes as well as in PTC samples with respect to their
normal counterparts, supporting the notion of an autocrine
TGFA/EGFR loop of signaling in PTCs.
Validation of TGFA and EGFR expressions in PTCs and
RET/PTC1-infected thyrocytes
We next analyzed TGFA and EGFR expression levels using a
dataset of PTC samples with known genetic mutations [9]. It is
worth noting that in this study, the normal thyroid tissues were
from pathologies other than thyroid cancer. TGFA expression was
significantly up-modulated in RAS-, BRAF-, and RET/PTC1-
mutated PTCs with respect to normal thyroid tissues (Fig. 2A, left
panel). No differences were observed for EGFR, with the only
exception of RAS-mutated PTCs (Fig. 2A, right panel).
Subsequently, real-time RT-PCR analysis of TGFA and EGFR
transcripts was performed on total RNA from 5 normal thyroid
tissue samples from pathologies other than thyroid cancer and 23
PTC biopsies (Table S1). TGFA transcripts were significantly
increased in all PTCs relative to normal thyroid samples (Fig. 2B,
left panel). No significant differences in EGFR expression were
detectable between the normal and tumor samples, as well as
within all PTCs tested with different genetic lesions (Fig. 2B, right
panel). The TGFA and EGFR expressions of the same samples
were then compared subdividing the tumors in primary lesions
(stage 1–2 and stage 3–4) and lymph nodal metastases (Fig. 2C).
TGFA transcripts were significantly higher in PTC metastases
when compared with normal thyroid samples, and although not
significant, TGFA levels trended upwards with tumor stage
(Fig. 2C, left panel). In addition, EGFR transcripts were also
trended upwards, although not significant (Fig. 2C, right panel).
We next performed real-time RT-PCR for TGFA and EGFR
on total RNA from normal and RET/PTC1-infected thyrocytes.
In agreement with the gene expression analysis (see Table 3),
TGFA and EGFR transcripts were increased to about 3.5- and 5-
fold in RET/PTC1-infected thyrocytes relative to normal cells
(Fig. 2D, left panel). Consistent with the bioinformatic analysis,
AREG transcript was de novo expressed at detectable levels in
RET/PTC1-infected thyrocytes. In addition, Western blot
analysis identified elevated EGFR protein and phosphoprotein
in total cell lysates from RET/PTC1-infected thyrocytes in
comparison with the lysates from normal thyrocytes (Fig. 2D,
right panel).
These data essentially validated the bioinformatic analysis
demonstrating the up-modulation of TGFA in PTCs, in RET/
PTC1-infected thyrocytes, and in the advanced stages of PTC
progression.
Majority of PTC cell lines expressed high levels of both
TGFA and EGFR
To elucidate the functional role of TGFA/EGFR, we analyzed
their protein levels in four PTC cell lines with known and
determined genetic lesions (see Table S2). An immortalized
thyrocyte cell line, N-Thy-ori3-1 [14], and the HeLa cell line
were included as controls for EGFR-expressing nontransformed
and tumor cells, respectively. Western blot analysis on total cell
lysates with anti-EGFR antibody (Ab) demonstrated EGFR
expression in all the cell lines tested, with TPC1, NIM-1, and B-
Dataset (no. of
samples) I (4) II (7) III (16) IV (6) V (8)
L/R Gene Symbol T/N P-value T/N P-value T/N P-value T/N P-value T/N P-value
(FDR) (FDR) (FDR) (FDR) (FDR)
(0.0271) (0.0005) (0.0043) (0.0769)
R ITGAV 1.25 0.0441 1.67 0.0008 1.43 0.0059
(0.1955) (0.0050) (0.1150)
R CD44 2.22 0.0043 1.67 0.0022 2.00 0.0000 1.67 0.0064 1.67 0.0009
(0.0799) (0.0352) (0.0000) (0.0251) (0.0486)
R ITGA9 1.59 0.0282 1.67 0.0032
(0.2010) (0.0087)
R ITGB1 1.67 0.0022
(0.0063)
1Modulation was calculated as mean ratio of paired tumor (T)/controlateral normal tissue (N) gene expression. An arbitrary threshold of Ligand or Receptor gene
expression modulation was settled at a P,0.01 (paired t-test) and/or FDR ,0.25 and the results were considered relevant if present in at least 3 datasets. Above this
arbitrary threshold, all the possible pairings with this L or R are reported. Significant ratios are in bold. The gaps mean that the T/N ratios were below the arbitrary
significant threshold.
doi:10.1371/journal.pone.0012701.t002
Table 2. Cont.
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anti-EGFR Ab showed comparable membrane expression of
EGFR on N-Thy-ori3-1 and in PTC cell lines (Fig. 3B). The
apparent discrepancy between the EGFR protein levels in western
blot and FACS analyses might be due to EGFR internalization
and accumulation in the cytoplasm in PTC cells.
Subsequently, we used ELISA to detect TGFA in conditioned
medium from the above-tested cells (Fig. 3C). NIM-1 and K1
conditioned media contained 50 and 150 pg/10
6 cells of TGFA,
respectively, and TPC1 medium contained low but evaluable
amount of TGFA. The conditioned media from the immortalized
N-Thy-ori3-1 thyrocyte and B-CPAP cell lines contained unde-
tectable levels of TGFA. As TGFA could not be completely
released from the cell membrane [15], we performed ELISA also
on total lysates from the same cell lines, but only trace amount of
endogenous TGFA was detectable in all the cell lines (data not
shown). On the other hand, B-CPAP cells appeared to express
AREG ligand by real-time RT-PCR (data not shown).
Thus, in vitro analysis showed that both immortalized
thyrocytes and PTC cell lines express EGFR but only PTC cells
secrete TGFA.
EGFR and TGFA are functional in the NIM-1 thyroid
cancer cell line
To evaluate the ability of the TGFA/EGFR signaling loop to
transduce signals in PTCs, NIM-1 cells were chosen as an in vitro
model. It is known that when TGFA interacts with EGFR, the
complex is internalized and eventually degraded in lysosomes [16].
Indeed, immunofluorescence (IF) analysis of fixed NIM-1 cells
using anti-EGFR Ab showed that in starved cells, EGFR was
Figure 1. Analysis of L/R pairs differentially expressed in normal or tumor thyroid samples. Correlation analysis of INHBB/ACVR1, TNC/
ANXA2, and TGFA/EGFR pairs in normal contralateral or thyroid cancer samples of dataset III (see Table 1) obtained by Pearson correlation. P values
are indicated.
doi:10.1371/journal.pone.0012701.g001
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24 h of TGFA stimulation, EGFR expression was detectable only
in small intracellular punctuate vesicles (right panel), suggesting an
endocytic mechanism of receptor degradation. These results
suggest that ligand-induced EGFR activation elicited the internal-
ization and intracellular sorting of the TGFA/EGFR complex.
Subsequently, we treated starved cells with 1 ng/ml of TGFA in
the absence or presence of Cetuximab, a chimeric anti-EGFR Ab
known to inhibit ligand binding to EGFR with 10-fold higher
affinity than endogenous ligands (either EGF or TGFA) [17], and
analyzed EGFR phosphorylation by immunoprecipitation (IP)
with anti-EGFR Ab and Western blotting with anti-phosphotyr-
osine (P-Tyr) Ab. EGFR was already phosphorylated in 24-h-
starved NIM-1 cells, but following TGFA stimulation, its
phosphorylation level was increased (Fig. 4B). Cetuximab
pretreatment lowered EGFR phosphorylation to levels below
those observed in starved cells. In HeLa cells, EGFR phospho-
protein was detectable only after TGFA treatment. The basal
EGFR phosphorylation observed in NIM-1 cells is consistent with
the hypothesis that endogenous TGFA contributes to EGFR
phosphorylation. Furthermore, EGFR phosphorylation was asso-
ciated with ERK and AKT phosphorylation, and Cetuximab
pretreatment reduced this phosphorylation to levels similar to
those observed in starved cells, indicating that the MEK/ERK
and PI3K/AKT pathways depend at least in part on EGFR
activation (Fig. 4B).
Starved HeLa cells did not produce detectable amount of
TGFA (data not shown) and showed no EGFR basal phosphor-
ylation. We subsequently tested the capability of NIM-1-
conditioned medium to activate EGFR in these cells. EGFR
phosphorylation was detectable after 5-min stimulation, decreased
slightly after 15-min stimulation, and remained stable after 60-min
treatment. ERK phosphorylation reached a maximum after
15 min of NIM-1-conditioned medium treatment and maintained
these levels for up to 60-min treatment (Fig. 4C). Phospho-AKT
increased slightly after 15-min treatment, reaching a maximum
after 30 min before disappearing after 60-min treatment. Pre-
treatment with either the tyrosine kinase inhibitor AG1478 or
Cetuximab blocked stimulation of EGFR phosphorylation. These
data support the presence of functional EGFR ligand/s, possibly
TGFA (see Fig. 3C), in the NIM-1-conditioned medium.
Altogether, these results show in vitro that TGFA/EGFR signaling
loop activates both MEK/ERK and PI3K/AKT pathways in
PTC cells.
TGFA/EGFR signaling contributes to the proliferation of
PTC cells
We next analyzed whether activated EGFR could be involved
in cell proliferation by monitoring NIM-1 cell growth for up to
72 h in the absence or presence of AG1478. AG1478 decreased
cell proliferation in a dose-dependent manner, with the highest
AG1478 dose apparently toxic after 48-h treatment (Fig. 5A, left
panel). As the NIM-1 cell line harbors a BRAF V600E mutation,
with the result that the MEK/ERK pathway is constitutively
activated, we investigated whether TGFA/EGFR signaling in this
cell line was dependent on RAF/MEK/ERK activation by
inhibiting MEK-dependent proliferation using the MEK inhibitor
UO126. An increase in the growth rate of starved NIM-1 cells was
detectable after 24-, 48-, and 72-h treatment with TGFA (Fig. 5A,
right panel). UO126 totally blocked cell growth, and TGFA
stimulation rescued growth capability, although the growth rate
did not reach a level similar to that of TGFA-stimulated cells
(Fig. 5A, right panel). Therefore, EGFR stimulation by TGFA
might be able to sustain PTC cell proliferation independent of the
MEK/ERK pathway.
To define the signaling pathway activated by TGFA/EGFR
loop when the MEK/ERK pathway was blocked, Western blot
analysis was performed on total cell lysates from 24-h-starved
NIM-1 cells stimulated for 24 h with TGFA alone or together with
UO126. In this experiment, AG1478 treatment was also included
to inhibit the tyrosine kinase activity of EGFR. In starved NIM-1
cells, phospho-ERK decreased upon UO126 treatment, while
phospho-AKT slightly increased (Fig. 5B). Phospho-ERK de-
creased only slightly in AG1478-treated cells. Furthermore, 24-h
TGFA stimulation induced both phospho-ERK and -AKT, an
effect offset by AG1478 treatment (Fig. 5B). Interestingly,
stimulation with TGFA in the presence of UO126 completely
abolished phospho-ERK, while phospho-AKT strongly increased;
treatment with both AG1478 and UO126 reversed this effect,
indicating that AKT phosphorylation is at least partially
Table 3. Comparison between the in vitro model and the
PTCs/normal samples.
L/R
Gene
Symbol
RET_PTC1/
Normal T/N*
I II III IV V
Concordant
L ANGPTL1 0.09 0.20 0.21
R TEK 0.19 0.70 0.63 0.63
L AREG 148.50 2.00
R EGFR 2.42 1.67 1.67 1.25
L BTC 9.46 1.25
R EGFR 2.42 1.67 1.67 1.25
L DTR 4.47 2.50
R EGFR 2.42 1.67 1.67 1.25
L TGFA 14.22 4.17 3.33 5.00
R EGFR 2.42 1.67 1.67 1.25
L FGF7 0.13 0.63
R FGFR2 0.03 0.40 0.43 0.26 0.83
L EFNA4 36.76 1.67
R EPHA4 2.59 2.22 2.00 3.33 1.43
L PLAU 21.22 4.35 2.50 10.00 2.50 3.33
R PLAUR 4.63 1.25 3.33
L SPP1 3.52 2.50 3.33 2.00 2.00
R CD44 3.70 2.22 1.67 2.00 1.67 1.67
L SPP1 3.52 2.50 3.33 2.00 2.00
R ITGA9 4.64 1.59 1.67
Discordant
L CXCL12 2.59 0.20 0.45 0.29 0.42
R CXCR4 107.10 0.40
L TNFSF10 3.55 0.40 0.50 0.77
R TNFRSF11B 2.23 0.10 0.19 0.18
L PGF 4.34 0.30 0.40
R NRP1 5.61 0.77
L TGFB2 0.28 1.25
R TGFBR1 0.48 1.43
*T/N values are from Table 2. See Table 2 legend for selection criteria.
Concordant or discordant L/R pairs between the in vitro model and clinical
samples.
doi:10.1371/journal.pone.0012701.t003
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decreased when the cells were treated with UO126, suggesting
that RAF/MEK/ERK pathway, constitutively activated in this
cell line, might regulate EGFR expression at transcriptional and/
or protein levels. Treatment with the PI3K inhibitor Ly294002
completely abolished phospho-AKT, indicating its dependency on
PI3K activation (data not shown). PI3K/AKT activation was not
owing to Her-3 expression, because Her-3 was never expressed in
NIM-1 cells (data not shown).
To investigate whether MEK inhibition could affect EGFR
expression at transcriptional levels, real-time RT-PCR was
performed on total RNA from NIM-1 cells treated with UO126
as shown earlier. EGFR expression decreased up to 2-fold in cells
treated with TGFA and UO126 (Fig. 5C). The results support the
hypothesis that constitutively activated RAF/MEK/ERK path-
way modulates not only protein stability but also EGFR transcript.
Altogether, these data demonstrate that TGFA/EGFR signaling
loop contributes to the growth of PTC cells, possibly by sustaining
PI3K/AKT pathway activation.
Discussion
In this study, we applied a combined bioinformatic and
biological approach to the analysis of signaling in PTC and found
that: i) the TGFA/EGFR pair emerged as one of the most tightly
regulated L/R pair as assessed by gene expression analysis in a
total of 92 PTC samples (41 of Table 1 and 51 from the dataset
obtained from the study by Giordano et al. [9]) and 41
contralateral tissues; ii) tumor thyroid tissues, as assessed by real-
time RT-PCR, expressed similar levels of EGFR transcripts
respect to normal thyroid tissues, but the levels of TGFA
transcripts were significantly elevated in PTCs, in particular those
with BRAF and RET/PTC mutations, and in larger or metastatic
tumors; iii) RET/PTC1 expression was associated with increased
EGFR and TGFA expressions in RET/PTC1-infected thyrocytes;
and iv) TGFA/EGFR signaling increased the growth of a BRAF-
mutated PTC cell line, possibly through PI3K/AKT activation,
independently from MEK/ERK signaling.
We found potentially activated L/R signaling loops in PTC by
interrogating a previously used L/R database [11]. As a proof-of-
principle, we had already applied the same bioinformatic
approach to ovarian cancer, but a list of the L/R pairs
coordinately expressed in tumors vs. normal ovary tissues was
not compiled, owing to the impossibility to have gene expression
data of normal tissue from the same ovarian cancer patient. The
major advantage in applying this bioinformatic tool to PTC resides
in the ability to compare coordinated L/R expressions in PTC vs.
the normal counterpart, thus highlighting only those L/R pairs
truly specific for tumor cells from thyroid origin in an intra-patient
analysis. Some internal validations emerged, such as the pairs
PLAU/PLAUR, SPP1/CD44, and SPP1/ITGA9, whose ligands
have been demonstrated overexpressed in thyroid tumors [12,13]
as well as in our in vitro model [6]. Furthermore, other L/R pairs
identified in our analysis, namely INHBB/ACVR1 and TNC/
ANXA2, have been shown to be involved in invasiveness of other
solid tumors [18,19], and as they have not yet been studied in
thyroid cancer, warrant further investigation in this context. The
correlation analysis among PTCs (see Fig. 1) highlighted an
inverse correlation between INHBB/ACVR1 and TGFA/EGFR
pairs. Note that the analysis reported in Table 2 refers to the up-
or down- modulation in PTCs respect to the normal controlateral
thyroid tissues within the same patient while the analysis shown in
Fig. 1 reports the correlation between the ligand and its receptor
separately in normal thyroid tissues or in PTC samples. These data
suggest that within the tumor the increased ligand expression
could down-modulate the expression of its receptor. The latter
observation is not in contrast with the overall slightly increased
receptor expression when comparing tumors to their normal
counterpart. Previous analysis of EGFR expression in thyroid
cancer also gave controversial results: some studies report up-
regulation in thyroid carcinomas, particularly in ATC, whereas
others report expression levels similar to those observed in normal
tissue (reviewed in [20]).
Within the biological classes of L/R pairs identified by our
analysis, the most represented class was that associated with
growth. Few association were observed with chemo/cytokine-
genes in PTCs, and in particular, the CXCL12/CXCR4 pair was
found to be downregulated in PTCs vs. normal contralateral
tissues. We had previously shown that de novo RET/PTC1
expression in normal thyrocytes induces a pro-inflammatory
program [6], and Castellone et al. showed that CXCR4 is
expressed in PTCs but not in normal thyroid tissues [21]. The
discrepancy between these studies and the current one could be
explained by the fact that while the expression of an oncogene,
such as RET/PTC1, is sufficient per se to induce the CXCL12/
CXCR4 pair and other inflammation-related genes in vitro,a
combination of mechanisms may be required to regulate these
genes in tumors. Moreover, our analysis compared gene
expression of PTCs with respect to the normal contralateral
counterpart, which could have a transcript profile different from
that of the normal thyroid tissue.
From the several L/R pairs that emerged from our analysis, we
chose the TGFA/EGFR signaling loop for further validation.
TGFA and EGFR have been previously found to be co-expressed
in thyroid cancer and have been associated with a more aggressive
disease [22,23]. Recently, gene expression analyses have identified
TGFA upregulation in thyroid carcinomas, especially in PTCs
[24,25]. In particular, Delys et al. showed a statistically significant
alteration of the EGF signaling pathway as well as other genes
involved in this cascade [26]. However, prior to the current study,
a functional TGFA/EGFR signaling loop has not been experi-
Figure 2. Validation of TGFA and EGFR expressions in PTCs. A. Analysis of TGFA and EGFR expression levels in dataset presented by Giordano
et al. [9]. Results are shown as relative expression. *, P,0.05 and **, P,0.0001: statistically significant results in comparison with normal samples (P
values were determined by two-tailed Student’s t-test with unequal variance). B. Real-time RT-PCR analysis of TGFA and EGFR genes in normal thyroid
(from pathologies other than cancer) and PTC specimens. Results are given as relative expression (mRNA expression normalized for PGK1 mRNA
levels). Medians are shown. *, P,0.05: statistically significant results in comparison with normal samples (P values were determined by two-tailed
Student’s t-test with unequal variance). C. Real-time RT-PCR analysis of TGFA gene in the same specimens reported in panel B, classified according to
tumor staging. pT1, tumors less than 1 cm and limited to the thyroid; pT2, tumors more than 1 cm but not more than 4 cm in greatest dimension
and limited to the thyroid gland; pT3, tumors more than 4 cm and limited to the thyroid; pT4, tumors displaying local extrathyroid spread; and M,
lymph nodal metastasis. **, P,0.0001: statistically significant result in comparison with normal samples (P values were determined by two-tailed
Student’s t-test with unequal variance). D. Left panel: Real-time RT-PCR analysis of EGFR, TGFA, and AREG genes in normal thyreocytes and RET/PTC1-
infected cells. Results are presented as relative expression (mRNA expression normalized for PGK1 mRNA levels). Right panel: biochemical analysis of
parental and RET/PTC1-infected thyrocytes. Cell extracts were analyzed with the following Abs: anti-RET (ret), anti-EGFR (EGFR), anti phosphorylated
EGFR (P-EGFR). b-actin is shown as a control for protein loading. One representative experiment of three is shown.
doi:10.1371/journal.pone.0012701.g002
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PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12701Figure 3. Majority of PTC cell lines expressed high levels of both EGFR and TGFA. A. Western blot analysis with anti-EGFR Ab was
performed on total cell lysates from PTC cell lines. Values corresponding to the densitometric evaluation of EGFR expression are shown at the
bottom. Abs used are indicated. b-actin is shown as a control for protein loading. B. FACS analysis on PTC cell lines stained with anti-EGFR Ab (dark
black peak), with a mouse IgG1 isotype control (grey dotted peak) or only with the secondary labelled Ab (black peak). C. TGFA production by thyroid
cell lines. Media without FBS were conditioned for 48 h by confluent cells and analyzed by ELISA. One representative experiment of two is shown.
doi:10.1371/journal.pone.0012701.g003
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showed that EGFR expression is not up-regulated in PTC samples
respect to normal thyroid tissues from pathologies other than
thyroid cancer (see Fig. 2). This discrepancy might be due to a
different and fine regulation of EGFR expression in PTC cells
respect to normal controlateral thyroid cells. Interestingly, we
Figure 4. EGFR and TGFA are functional in NIM-1 thyroid cancer cell line. A. IF analysis with anti-EGFR Ab on serum-starved NIM-1 cells left
untreated or treated with 100 ng/ml TGFA for 24 h. B. Biochemical analysis on HeLa and NIM-1 cell extracts. After serum starvation for 24 h, the cells
were left untreated or treated with 100 nM Cetuximab, or control chimeric Ab (data not shown) for 2 h, and then stimulated with 1 ng/ml TGFA for
5 min. Abs used are indicated. EGFR phosphorylation has been analyzed by immunoprecipitation (IP) with anti-EGFR Ab and western blotting with
anti-phosphotyrosine Ab (P-Tyr). b-actin is shown as a control for protein loading. C. Western blot analysis on HeLa cell extracts. After serum
starvation for 24 h, the cells were exposed to fresh medium without FBS (-) or to conditioned medium of NIM-1 cells for 1 h. Pretreatment with
AG1478, Cetuximab, or control chimeric Ab (data not shown) was performed for 2 h, and then NIM-1 conditioned medium was added to the culture.
As control of specific Ab inhibition, the cells were treated with an unrelated human Ab. Abs used are indicated. b-actin is shown as a control for
protein loading. One representative experiment of three is shown.
doi:10.1371/journal.pone.0012701.g004
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PLoS ONE | www.plosone.org 12 September 2010 | Volume 5 | Issue 9 | e12701Figure 5. TGFA/EGFR signaling contributes to the proliferation of PTC cells. A. NIM-1 cells were exposed to solvent or to different drugs for
up to 72 h in medium without FBS. Cell proliferation was evaluated by SRB assay. Representative growth curves are shown. Each point represents the
mean of eight independent replicates 6 SD. B. Western blot analysis was performed on total cell lysates from starved NIM-1 cells unstimulated or
stimulated with 100 ng/ml of TGFA for 24 h. When indicated, the cells were also treated with AG1478 and/or UO126. Abs used are indicated. b-actin
is shown as a control for protein loading. One representative experiment of four is shown. C. Real-time RT-PCR analysis of EGFR gene in NIM-1 cells
treated with the MEK1/2 inhibitor UO126. Serum-starved cells were exposed to solvent (-) or to 10 mM UO126 in the presence of 100 ng/ml of TGFA.
Total RNA was extracted after 24 h. The results are presented as relative expression (mRNA expression normalized for PGK1 mRNA levels). *, P,0.05:
statistically significant result in comparison with cells exposed to solvent (P value was determined by two-tailed Student’s t-test with unequal
variance).
doi:10.1371/journal.pone.0012701.g005
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well in metastasis. These results, together with the fact that NIM-1
cells derived from a PTC metastasis to the sacral bone, await
further analysis on a large number of PTC samples to validate a
possible association between TGFA expression and PTC progres-
sion. On the other hand, PTC samples and cell lines expressing
low TGFA levels might represent a PTC subtype expressing other
EGFR ligands such as AREG, as already observed [26].
Our data provide several lines of evidence that a TGFA/EGFR
signaling loop is significantly associated with PTC harboring
BRAF and RET/PTC mutations. So far, it is known that both
alterations lead to the activation of common downstream MAP
kinase pathway [5]. In this study, we showed that in NIM-1 cells
the MEK kinase inhibitor UO126 impaired cell growth.
Interestingly, in TGFA-stimulated NIM-1 cells, PI3K/AKT
signaling increased after the inhibition of MEK pathway, and
was decreased by the tyrosine kinase inhibitor AG1478 together
with the MEK inhibitor UO126. These results argue that PI3K/
AKT pathway is partially dependent on TGFA/EGFR signaling,
an observation that could have important implications in
developing therapeutic PTC compounds directed against targets
other than the MEK/ERK pathway. Furthermore, it seems
envisagable that the same mechanism could also be active in other
tumors with high BRAF mutation frequency, such as melanomas
[27].
Recently, RET/PTC was found to be associated with EGFR in
thyroid PCCL3 cells, thus contributing to cell growth by
modulating RET/PTC phosphorylation and conditional RET/
PTC expression up-modulated EGFR protein and phosphoprotein
levels [28]. Consistent with these findings, we have shown here
that in RET/PTC1-infected thyrocytes, EGFR expression was
upregulated at the transcriptional level. We also observed that
EGFR transcript levels were significantly lower in RAS-mutated
PTC when compared with the normal counterpart. These results
are consistent with the fact that RAS mutations are mostly present
in the follicular variant of PTCs and that this mutation correlates
with specific gene expression profiles [9]. Indeed PTCs harboring
RAS mutation show significantly less prominent nuclear features
of the tumor, more frequent encapsulation, and low-rate lymph
node metastases [4].
Interference with EGFR activation has been previously
considered in the therapy of thyroid cancers. A phase II study of
gefitinib in patients with advanced thyroid cancer showed that the
drug was poorly effective in curing patients – disease stabilization
was observed in only 32% of patients [29]. In this study, we have
shown that constitutive active MEK/ERK signaling, owing to
BRAF mutation, may function in tandem with EGFR signaling.
Thus, EGFR intervention alone seems to be insufficient in the
treatment of thyroid cancer.
In conclusion, compiling a reliable list of L/R pairs associated
with PTC progression and validating the biological role of the
autocrine TGFA/EGFR loop in thyroid cancer, in vitro, have
enabled us to better understand the biology of BRAF- and RET/
PTC-mutated PTCs and to identify potential new tools for
diagnosis and therapeutic intervention.
Materials and Methods
Ethics statement
All patients whose biological samples were included in the study
signed an informed consent, approved by the Independent Ethical
Committee of the Fondazione IRCCS Istituto Nazionale dei
Tumori, Milano (Italy), to donate the leftover tissue specimens
after completing diagnostic procedures to the Fondazione IRCCS
Istituto Nazionale dei Tumori for research purposes.
Bioinformatic analysis
We interrogated 5 datasets of gene expression profiles from
thyroid carcinoma samples with a list of 511 L/R (DLRP-rev1)
pairs involved in autocrine/paracrine signaling, as previously
described [11]. We considered 5 datasets, obtained with Affimetrix
platforms, of 41 PTCs and the corresponding normal contralateral
thyroid tissue samples (Table 1). Follicular thyroid carcinoma and
all the other samples from different thyroid diseases were excluded
for this analysis. When multiple probe sets or clones matching a
single gene (either L or R) were present, each one was considered
separately. Pearson’s correlation coefficient was computed and a P
value was assigned for each L/R pair in each dataset; the
Bonferroni correction was applied because multiple tests were
performed. Ligand and Receptor from pairs significantly corre-
lated in at least 1 dataset were subsequently analyzed separately
across the other datasets and were considered modulated when the
gene expression of a partner of the pair was concordantly
modulated at P,0.01 and/or FDR,0.25 in at least 3 datasets.
TGFA and EGFR gene expression data of 51 PTCs, harboring
known genetic mutations, and 5 normal thyroid tissues from
pathologies other than thyroid cancer, reported in another
publicly available dataset obtained on Affimetrix platform [9],
were analyzed for possible correlations between expression levels
and genetic mutations.
Antibodies (Abs) and reagents
The following monoclonal Abs were used in blotting experi-
ments: anti-phospho-tyrosine, clone 4G10, from Upstate Biotech-
nology (Lake Placid, NY); anti-MAP kinase activated (pERK1/2)
from Sigma-Aldrich; and anti-phospho-AKT (Ser473), clone D9E,
from Cell Signaling Technology. The following rabbit polyclonal
Abs were used in blotting experiments: anti-phospho-EGFR
(Tyr1173), anti-EGFR, and anti-Ret from Santa Cruz Biotech-
nology; anti-MAP kinase (ERK1/2) and anti-actin from Sigma-
Aldrich; and anti-AKT from Cell Signaling Technology. The goat
polyclonal Ab anti-EGFR from R&D Systems (Minneapolis, MN)
was used in IP experiments. The following reagents were used in
FACS experiments: the anti-EGFR monoclonal Ab MINT-5
(IgG1) [30] an affinity purified mouse IgG1 from eBioscience, as
isotype control, and fluorochrome-conjugated secondary Ab
(Becton Dickinson, Franklin Lakes, NJ). TGFA, and AG1478/
Tyrphostin were from Sigma-Aldrich. The MEK inhibitor UO126
was from Promega and the PI3K inhibitor Ly294002 was from
Calbiochem (La Jolla, CA); ErbituxH was used for Cetuximab.
TaqManH Gene Expression Assays were from Applied Biosystems
(Foster City, CA), ELISA for TGFA dosage was from R&D
Systems; and fluorochrome-conjugated Alexa Fluor 488 secondary
Ab was from Molecular Probes (Invitrogen San Francisco, CA).
Cell Culture
Five human thyroid cell lines were used in the present study:
Normal immortalized N-Thy-ori3-1 [14] and PTC-derived NIM-
1 [31], TPC1, B-CPAP [32], and K1 (European Collection of Cell
Cultures, ECACC, Porton Down Salisbury, UK) cells. The
mutational status of these cell lines are reported in Table S1.
Genomic sequence on DNA from NIM-1 cells detected no
mutation in EGFR gene (data not shown). Primary cultures of
normal human thyroid cells infected with retroviral vectors
containing RET/PTC1 oncogene were previously described [6].
HeLa cells (ATCC) were also used. All cell lines were maintained
in DMEM with 10% fetal bovine serum (FBS), except for N-Thy-
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RPMI-1640 and in DMEM:HAM’S F12:MCDB 105 (2:1:1)
supplemented with 10% FCS, respectively. The cells were
maintained at 37uC in a humidified incubator under 5% carbon
dioxide.
Tumor Samples
Thyroid samples, 5 normal and 23 papillary thyroid carcino-
mas, were selected for this study (Table S2). The normal thyroid
tissues were from patients with pathologies other than thyroid
cancer. The samples were collected at the Department of
Pathology at the Fondazione IRCCS Istituto Nazionale dei
Tumori (Milan, Italy) from 1984 to date. Genetic lesions were
characterized as previously described [8].
RNA Extraction and real-time RT-PCR Analysis
Total RNA from tissue specimens was extracted essentially as
described earlier [8]. For each sample, 20 ng of template was
amplified in PCR reactions carried out in triplicate on an ABI
PRISM 7900 using TaqManH Gene Expression Assay (Applied
Biosystems). EGFR, TGFA, and AREG were tested. PGK1 was
used as housekeeping gene. Data analysis was performed using the
SDS (Sequence Detection System) 2.2.2 software.
FACS and IF analyses
Membrane evaluation of EGFR expression was performed as
described earlier [33]. For IF analysis, cells grown on monolayer
were fixed with 2% buffered paraformaldehyde and permeabilized
with 0.2% Triton-X100. Incubations with primary and secondary
Abs were performed essentially as described earlier [34]. The
samples were analyzed using an Eclipse TE2000-S microscope
with a 40X PanFluor objective (Nikon). Images were acquired with
ACT-1 software (Nikon) at a resolution of 225061800 pixels.
ELISA
The supernatants of the indicated cell lines, maintained in
serum-free medium for 48 h, were analyzed. The amounts of
TGFA released in the supernatant were quantified by ELISA with
a commercial kit by R&D Systems. The results were normalized
for cell density.
Western blotting and IP
The total cell lysates, Western blotting, and IP were performed
essentially as described earlier [35]. The blots were viewed and
analyzed using ChemiDoc XRS and the Quantity OneH software
(Bio-Rad, Hercules, CA).
Cell Proliferation
Cells were seeded at 20,000 cells/cm
2 density in 96-well plates
in the presence of DMEM with 10% FBS. The day after seeding,
the cells were serum starved and exposed to solvent or different
concentrations of drugs as indicated. Cell growth was evaluated by
sulforhodamine B (SRB) colorimetric assay after 24, 48, and 72 h
of treatment as previously described [36]. The experiment was
performed in eight replicates.
Statistical analysis
GraphPad Prism software (GraphPad Software, San Diego, CA)
was used to analyze all the data. Significance of differences was
determined by Student’s t-test.
Supporting Information
Table S1 Characteristics of the PTC cell lines used.
Found at: doi:10.1371/journal.pone.0012701.s001 (0.03 MB
DOC)
Table S2 Characteristics of the PTC tissue samples analyzed by
real real-time RT-PCR.
Found at: doi:10.1371/journal.pone.0012701.s002 (0.05 MB
DOC)
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